Anti-Diabetic Medications: A promising therapeutic approaches for the Management of NAFLD | ||||
Records of Pharmaceutical and Biomedical Sciences | ||||
Article 8, Volume 5, Pharmacology-Pharmaceutics, January 2021, Page 65-70 PDF (572.1 K) | ||||
Document Type: Mini-reviews | ||||
DOI: 10.21608/rpbs.2021.79353.1103 | ||||
View on SCiNiTO | ||||
Authors | ||||
ahmed ibrahim 1; Reem mohamed Hazem 2; Dina Abdelkarim Ali3; Yasser mohamed Moustafa 4 | ||||
1Department of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt | ||||
2Department of Pharmacology &Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt. | ||||
3Department of clinical Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt | ||||
4Pharmacology and Toxicology Department, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt. | ||||
Abstract | ||||
Type 2 diabetes and Nonalcoholic fatty liver disease are two of the most common metabolic diseases in the world, with an increasing prevalence. Patients with T2DM have a two-fold increased risk of developing NAFLD, The evidence that certain antidiabetic drugs boost NAFLD/NASH in T2DM patients is growing. However, there are no specific pharmacologic treatments available. This review aims to outline the data supporting the effectiveness of anti-diabetic drugs in the treatment of NAFLD, besides providing an overview of novel anti-diabetic therapies that have been proposed to achieve this goal. Most of these anti-diabetic agents demonstrate short-term efficacy, but have shown little to no impact on hepatic histology. Only thiazolides and GLP-1 receptor agonists have shown considerable improvement in hepatic histology. | ||||
Keywords | ||||
GLP-1; Steatohepatitis; Diabetes; NAFLD | ||||
Statistics Article View: 273 PDF Download: 285 |
||||